The zinc-finger protein A20/TNFAIP3, an inhibitor of nuclear factor-jB (NF-jB) activation, has been shown to protect MCF-7 breast carcinoma cells from TNFainduced apoptosis. As estrogen receptor (ER) status is an important parameter in the development and progression of breast cancer, we analysed the effect of 17b-estradiol (E 2 ) treatment on the expression of A20. We found that A20 is a new E 2 -regulated gene, whose expression correlates with ER expression in both cell lines and tumor samples. With the aim of investigating the impact of A20 expression on MCF-7 cells in response to ER ligands, we established stably transfected-MCF-7 cells overexpressing A20 (MCF-7-A20). These cells exhibited a phenotype of resistance to the 4-hydroxytamoxifen cytostatic and pro-apoptotic actions and of hyper-response to E 2 . Dysregulations in bax, bcl2, bak, phospho-bad, cyclin D1, cyclin E2, cyclin D2 and cyclin A2 proteins expression were shown to be related to the resistant phenotype developed by the MCF-7-A20 cells. Interestingly, we found that A20 was also overexpressed in MVLN and VP tamoxifen-resistant cell lines. Furthermore, high A20 expression levels were observed in more aggressive breast tumors (ER-negative, progesterone receptor-negative and high histological grade). These overall findings strongly suggest that A20 is a key protein involved in tamoxifen resistance, and thus represents both a new breast cancer marker and a promising target for developing new strategies to prevent the emergence of acquired mechanisms of drug resistance in breast cancer.
Introduction
Breast cancer is the most common cancer among women in developed countries, and about 70% of these tumors express estrogen receptor (ER). Estrogens participate in the development and the progression of breast carcinoma (Pike et al., 1993) , and measurement of ER-alpha (ERa) expression has allowed an accurate prediction of response to endocrine therapy (Honig, 1996) . ERpositive (ER þ ) tumors are associated with a welldifferentiated phenotype and a better prognosis than ER-negative (ERÀ) breast tumors (Pichon et al., 1996) . The selective ER modulator (SERM) tamoxifen (Tam) has been shown to be an effective adjuvant therapy for ER þ tumors by reducing the contralateral breast cancer by 50% (EBCTC Group, 1998) . However, only 60% of ER þ tumors respond to this adjuvant therapy, and prolonged Tam-treatment results in the appearance of Tam-resistant tumor cells (Johnston, 1997) . As the molecular mechanisms leading to Tam resistance are not fully understood, the identification of gene expression variations that might play a critical role in the development or the signature of Tam resistance is of much interest.
The zinc-finger protein A20, also called 'tumor necrosis factor a-induced protein 3 (TNFAIP3),' was first identified as a tumor necrosis factor a (TNFa)-inducible response protein in human umbilical vein endothelial cells (Dixit et al., 1990) . A20 is expressed in a variety of cell types in response to TNFa and to other numerous stimuli such as IL-1, CD40 cross-linking, Epstein-Barr virus latent membrane protein 1, lipopolysaccharide, hepatitis C virus core protein and influenza virus infection (Dixit et al., 1990; Laherty et al., 1992; Sarma et al., 1995; Tewari et al., 1995; Nguyen et al., 2006; Onose et al., 2006) . A20 gene expression is known to be mediated through activation of transcription factor NF-kB (nuclear factor-kB) (Krikos et al., 1992; Sarma et al., 1995) . In vitro transcription assays demonstrated that NF-kB could act in synergy with the Sp1 protein to allow the rapid induction of A20 transcription (Ainbinder et al., 2002) . Under physiological conditions, A20 expression was shown both to inhibit TNFa-induced necrosis in fibroblast cell lines (Heyninck et al., 1999) and to protect in a dosedependent manner primary endothelial cells from the programmed cell death induced by TNFa and IL-1 Jaattela et al., 1996; Ferran et al., 1998) . These observations were strengthened by two other studies, which demonstrated that A20-deficient mice developed exacerbated susceptibility to TNFastimulated apoptosis (Lee et al., 2000) , and that A20 overexpression protects the islets of Langerhans or the b-cells from IL-1b-, interferong-or TNFa-induced apoptosis (Grey et al., 1999) . In addition, high A20 expression was detected in breast carcinoma cells resistant to TNFa-mediated apoptosis . However, the A20 anti-apoptotic activity seems to be dependent on the cellular context since no protection from TNFa-induced apoptosis was observed in HeLa or kidney epithelial 293 cells (Janicke et al., 1994) . Thus, depending on both the stimulus and the cellular context, A20 can also exhibit pro-apoptotic activity. Indeed, its expression can promote cell death in response to oxidative stress through a negative-feedback loop, which blocks NF-kB activation and cellular survival (Storz et al., 2005) . Recent data suggest that A20-mediated inhibition of NF-kB occurs through the cooperation between the A20 and the ABIN-1 proteins, leading to the de-ubiquitination of NEMO/IKKg (Mauro et al., 2006) . The fact that A20 might control survival pathways has led to the hypothesis that A20 could be involved in tumorigenesis events. Indeed, A20 expression was also found to be correlated with the differentiation stages of nasopharyngeal carcinoma, suggesting its role in the pathogenesis and aggressiveness of these epithelial tumors (Codd et al., 1999) . Recently, A20 expression has been closely associated with resistance to O6-alkylating agents in glioblastoma cells and proposed as a predictive marker associated with patient survival (Bredel et al., 2006) .
As overexpression of A20 is associated with the development of resistance to TNFa-mediated apoptosis in the breast tumor cell-line MCF-7 , we hypothesized that A20 could also be a survival factor involved in the development of Tam resistance in breast cancer. In this report, we have investigated the modulation of A20 gene expression in the MVLN cell line, an ERa-positive and hormone-responsive human breast carcinoma cell line derived from the ER þ breast tumor cell line MCF-7 (Demirpence et al., 1993) . We explored A20 gene expression of MVLN cells in response to three ligands of ER: E 2 , the SERM 4-hydroxy-tamoxifen (OH-Tam), and the pure antagonist ICI 182,780. We then investigated whether A20 expression was correlated with ERa status by measuring A20 expression in ER þ or ERÀ breast cancer cell lines and breast tumor samples. We also explored the involvement of A20 overexpression in the cellular response to E 2 and OH-Tam pharmacological treatments. We show for the first time that A20 is a new estrogen-regulated gene involved in the development of OH-Tam resistance in ER þ cells and whose expression is correlated in breast cancer tumors with poor prognostic markers. These data strongly support the hypothesis that A20 is implicated in resistance to Tam and suggest that A20 could be used as a predictive or prognostic marker in the treatment of breast cancer.
Results

E 2 and OH-Tam treatments downregulate A20 gene expression in MVLN cells
The ability of A20 to protect breast carcinoma cells against apoptosis signaling prompted us to analyse the modulation of A20 gene expression in the context of the E 2 -induced survival pathway and OH-Tam-induced cytostatic response. To this end, the MVLN cell line, an ERa-positive and hormone-responsive human breast carcinoma cell line derived from MCF-7 (Demirpence et al., 1993) , was cultured in steroid-depleted dextrancoated charcoal (DCC) medium for 4 days and then supplemented with either 10 À9 M E 2 or 2 Â 10 À7 M OHTam for 6, 18 and 96 h. The levels of A20 mRNA expression were then monitored by real-time quantitative-PCR. Figure 1 shows a strong downregulation of A20 expression both in the presence of E 2 or OH-Tam, with respectively a À3.7-and À4.0-fold change (FC) observed after 96 h of treatment. Time-course studies also revealed that although E 2 and OH-Tam treatments led to a similar amplitude of variation after 96 h of culture, the downregulation of A20 gene expression occurred earlier in the presence of E 2 than under OHTam exposure (FC ¼ À3.1 in the presence of E 2 , and FC ¼ À1.3 in the presence of OH-Tam after 18 h of culture). These data strongly suggest that E 2 and OHTam regulate A20 expression by different mechanisms. On the contrary, treatment of MVLN cells for 96 h with the pure ER antagonist ICI 182,780, resulted in an increase of A20 expression (FC ¼ þ 2.7), demonstrating the specificity of the E 2 and OH-Tam activities.
We then measured the E 2 -driven transactivation of a luciferase reporter gene linked to the A20 promoter in MCF-7 cells (Figure 2) . A control experiment was performed by validating the induction of luciferase activity ( þ 5.4-fold) under E 2 treatment in ERE-Luc transfected-MCF-7 cells. Figure 2 shows that E 2 -induced downregulation of luciferase activity of A20-Luc transfected-MCF-7 cells (À4.3-fold), demonstrating that the E 2 -regulation of A20 gene expression occurs at the transcriptional level. Taken together, these data demonstrate for the first time that A20 is a new estrogenregulated gene, and that OH-Tam exerts agonistic activity (i.e., mimicking the action of E 2 ) on A20 gene expression regulation.
A20 is highly expressed in ERÀ breast cancer cell lines
We analysed A20 mRNA levels in four ER þ (MCF-7, ZR-75-1, T-47D and BT-474) and four ERÀ (MDA-MB-175, MDA-MB-231, MDA-MB-435 and MDA-MB-453) breast cancer cell lines. A20 mRNA expression was significantly higher (Po10
À4
) in ERÀ than in ER þ cell lines (Figure 3a) . Accordingly, A20 protein expression in two representative clones of ER þ and ERÀ cell lines perfectly correlated with A20 mRNA levels ( Figure 3b ). These data demonstrate that A20 expression is correlated with the ER status of breast cancer cell lines, strengthening our finding that ER-dependent signaling regulates A20 expression.
Constitutive expression of A20 protein confers resistance to OH-Tam-induced cytotoxicity The fact that A20 expression was repressed in OH-Tamtreated MVLN cells suggested that its anti-apoptotic activity might be involved in OH-Tam activity. To test this hypothesis, stable breast carcinoma MCF-7 cells, constitutively overexpressing the A20 protein, were established. To this aim, MCF-7 cells were transfected with either the eukaryotic expression pCIneo vector containing the full-length cDNA sequence of A20 (MCF-7-A20) or with the empty vector (MCF-7-pCIneo) and selected in the presence of G418. The data for two representative cellular clones from each population (MCF-7-pCIneo-1E8, MCF-7-pCIneo-3B3, MCF-7-A20-1F8 and MCF-7-A20-2C6) are presented in Figure 4 . A20 mRNA levels were 5-and 10-fold greater in the MCF-7-A20-2C6 and the MCF-7-A20-1F8 cells, respectively, than in the two MCF-7-pCIneo cell lines (Figure 4a ). Accordingly, A20 protein expression was increased by eight and sixfold in the MCF-7-A20-1F8 and the MCF-7-A20-2C6 cells, respectively, in comparison with the MCF-7-pCIneo cells (Figure 4b ).
The selected clones were cultured for 4 days in DCC medium in the presence or the absence of OH-Tam. Cell viability was then measured by cytotoxicity assay, and results presented in Figure 5 strikingly show a reproducible and significant (Po10 À6 ) diminution of OHTam-induced cytotoxicity in both the MCF-7-A20-1F8 and the MCF-7-A20-2C6 cells, in comparison with the MCF-7-pCIneo cells. Indeed, in the MCF-7-A20-1F8 and MCF-7-A20-2C6 cells, OH-Tam-induced cytotoxicity was reduced by two to fourfold, demonstrating that A20 overexpression modulates the cellular response to OH-Tam and exerts a protective effect. The amplitude of this protection was dependent on the amount of A20 expression since the maximal protective effect was observed with the MCF-7-A20-1F8 cellular clone, which exhibits the highest level of A20 expression (Figure 4 ). Because cell proliferation could influence the cellular response to OH-Tam, we excluded the possibility that the variations in A20 protective effect observed between the MCF-7-pCIneo and the MCF-7-A20 cells were the result of differences in the growth rate of the selected clones. Investigation of the proliferation rate of each cellular clone gave similar values, excluding this possibility (data not shown). We also determined whether diminution of the OH-Tam response observed in the A20-overexpressing cells was owing to a loss or a diminution of ER expression. Western blot analysis performed on MCF-7-pCIneo-1E8, MCF-7-pCIneo-3B3, MCF-7-A20-1F8 and MCF-7-A20-2C6 cell extracts did not reveal any difference in ERa expression between the four cellular clones tested (data not shown), excluding this possibility.
To study the specificity of the resistant phenotype conferred by A20 expression, we explored the viability of the MCF-7-pCIneo and MCF-7-A20 cells in the presence of other cytotoxic stimuli: OH-Tam, ICI 182,780, taxol, and gemcitabine. Table 1 demonstrates that, compared with MCF-7-pCIneo cells, the MCF-7-A20 cells displayed a 4.6-, a 533-fold and a 3.7-fold relative resistance to OH-Tam, ICI 182,780 and taxol, respectively. In contrast, the MCF-7-pCIneo and MCF-7-A20 cells did not display any difference in their response to gemcitabine (relative resistance ratio ¼ 1.3).
Constitutive A20 expression confers resistance to OH-Tam-induced apoptosis activity in MCF-7 cells Whereas A20 is an anti-apoptotic protein in most cells Jaattela et al., 1996; Ferran et al., 1998) , A20 also exerts proapototic action in specific cellular contexts or in response to specific stimuli (Janicke et al., 1994; Patel et al., 2006) . We thus decided to investigate the impact of A20 expression on the OHTam proapoptotic action in the MCF-7-pCIneo and MCF-7-A20 cell lines. Apoptotic cells were stained with FITC-Annexin-V and analysed by flow cytometry in three independent experiments ( Figure 6 ). We confirmed (Zhang et al., 1999 ) that OH-Tam was able to elicit cell death in MCF-7-pCIneo cells (16.4% of OH-Tamtreated cells versus 5.9% of untreated cells underwent apoptosis, Po0.005). On the contrary, OH-Tam treatment did not elicit any significant apoptotic response in MCF-7-A20 cells (7.2% in OH-Tam-treated versus 8.1% in untreated cells). One hallmark of apoptosis is the change in the bcl2 family proteins. Therefore, we evaluated the effect of A20 on the protein levels of bax, bak, bcl2 and phospho-bad in the MCF-7-A20 and MCF-7-pCIneo cells under OH-Tam exposure. We observed that the pro-apoptotic action of OH-Tam on MCF-7-pCIneo cells was associated with upregulation of the pro-apoptotic protein bax (Figure 7a ) and downregulation of the antiapoptotic protein bcl2 (Figure 7c ). In the MCF-7-A20 cells, where OH-Tam lost its apoptotic activity, we observed first the overexpression at the constitutive level of the antiapoptotic bcl2 protein (Figure 7c Constitutive A20 expression confers hypersensitivity to E 2 and resistance to the OH-Tam cytostatic activity in MCF-7 cells It is well established that under deprivation of estrogens or blockade of estrogen action with Tam, breast tumor cells develop hypersensitivity to the growth-stimulating action of E 2 (Martin et al., 2003; Berstein et al., 2004; Santen et al., 2004) . Moreover, during the development of Tam resistance, the first step is the loss of the Tam cytostatic activity before the development of increased sensitivity to the agonistic properties of Tam (Gottardis and Jordan, 1988; Ring and Dowsett, 2004) . In particular, we had previously observed that two OHTam-resistant MCF-7 cell lines had developed an increased sensitivity to E 2 growth-stimulating activity, a loss of sensitivity to OH-Tam cytostatic activity (with enhanced sensitivity to OH-Tam agonism), and a resistance to OH-Tam-induced apoptosis (Vendrell et al., 2005) .
To test whether the A20-mediated resistance to OHTam cytotoxicity was associated with modified cell proliferating responses to E 2 and OH-Tam, the MCF-7-pCIneo and MCF-7-A20 cell lines were cultured in DCC medium and then supplemented for 4 days with either vehicle, E 2 , OH-Tam, or both E 2 and OH-Tam. For each experimental condition, cell proliferation was monitored by the BrdU labeling method. As expected, E 2 exerted a growth stimulatory activity on the MCF-7-pCIneo cells, which was fully antagonized by the cytostatic activity of OH-Tam (Figure 8) . Strikingly, the amplitude of E 2 stimulation of cell proliferation was significantly higher in the MCF-7-A20 cell line than in the MCF-7-pCIneo cells (3.3-fold), demonstrating that A20-overexpressing cells possess functional ER and that the cells are hypersensitive to E 2 (Figure 8 ). In previous work (Vendrell et al., 2005) , we demonstrated that the increased sensitivity of OHTam resistant cells to the E 2 growth-stimulating activity was correlated at the gene/protein expression level by either the detection of new E 2 -induced gene/protein expression variations or by the increase of the amplitude of the E 2 -response measured in the nonresistant cells. In the present work, hyper-response to E 2 was validated in MCF-7-A20 cells for four proteins involved in the positive regulation of cell proliferation: (i) cyclin D1 (upregulation of cyclin D1 protein expression in MCF-7-A20 cells not detected in MCF-7-pCIneo cells, Figure 7e ) and (ii) cyclin D2, cyclin E2, cyclin A2 (respectively, Figure 7f , g and h showing in the MCF-7-A20 cells an increase of the amplitude of the E 2 response detected in MCF-7-pCIneo cells).
Furthermore, data presented in Figure 8 provide evidence that constitutive A20 overexpression also confers total resistance to the cytostatic action of OHTam. Proliferation of the MCF-7-A20 cells, observed in the presence of both E 2 and OH-Tam, also suggested that in these A20-overexpressing cells, OH-Tam was still able to prevent the binding of E 2 to ER (proliferating response null) but unable to exert its normal cytostatic activity. These findings clearly demonstrate that A20 overexpression confers a phenotype of OH-Tam resistance in MCF-7 cells by eliciting both the cytostatic and the pro-apoptotic activities of the drug. Moreover, by developing both hypersensitivity to E 2 and a resistance to OH-Tam, the MCF-7-A20 cells display a striking phenotype very similar to that previously observed in OH-Tam-resistant cellular clones obtained after 6-month-OH-Tam treatment of MCF-7 cells (Badia et al., 2000; Vendrell et al., 2005) .
A20 is overexpressed in Tam-resistant cell lines
Tam-resistant breast tumors display cellular disturbances such as gene expression variations, which might play a critical role in the development or the signature of the resistance. Our finding that A20 is able to inhibit the OH-Tam action in MCF-7 breast tumor cell lines makes it a good candidate to explain the emergence of Tam resistance. Consistent with this idea, Tam-resistant cell lines should express a higher level of endogenous A20 expression than Tam-sensitive cells. We thus explored A20 expression in two Tam-resistant cellular models, the MVLN and the VP cell lines. The MVLN cells were maintained under OH-Tam treatment for 6 months, allowing the emergence of OH-Tam-resistant but still estrogen-dependent cellular clones (Badia et al., 2000) . Two of these clones, called CL6.8 and CL6.32, have been previously characterized (Vendrell et al., 2005) . VP229 is a Tam-sensitive cell line established from a primary breast tumor removed before any pharmacological treatment, whereas VP267 was derived from the same patient after a local recurrence following Tam treatment (McCallum and Lowther, 1996) . Strikingly, RTQ-PCR experiments demonstrated in both the MVLN/CL6.8/CL6.32 and the VP229/VP267 cell lines that A20 mRNA expression was increased in the resistant cells. Indeed, compared with the MVLN cells, the CL6.8 and CL6.32 cells showed a twofold increase in A20 mRNA levels (Table 2) , which was validated at the protein level by Western blot analysis (A20 protein expression was two to threefold greater in the OH-Tam-resistant cells than in the MVLN cell line, data not shown). Moreover, compared with the VP229 cells, the Tam-resistant VP267 cell line displayed an 18-fold increase in A20 expression. The concordance of these data in two distinct cellular models of Tam resistance strongly suggests that A20 plays a role in the development of acquired Tam resistance in breast cancers. Relationship between A20 mRNA expression and clinical status in breast tumor samples Because a high level of expression of genes involved in the mechanisms of chemoresistance has frequently been associated with tumor aggressiveness, we explored the relationship between A20 expression and the clinical status of a collection of breast tumors. To this aim, tissue samples from primary breast tumors excised from 69 postmenopausal women were obtained and classified into subgroups according to the ER status, the PR status and the histological grade (Table 3 ). As shown above for the ER þ and ERÀ breast cancer cell lines, A20 mRNA expression was significantly greater in ERÀ than in ER þ breast tumor samples (P ¼ 0.0002, MannWhitney test) (Table 3) . Using the Spearman rank correlation test, we also found a significant negative correlation between the mRNA levels of A20 and ERa measured by RTQ-PCR (Spearman rank correlation coefficient ¼ À0.25; P ¼ 0.03). In addition, A20 mRNA expression was significantly greater in the PRÀ than in the PR þ breast tumors samples (P ¼ 0.0006), and significantly more expressed in tumor samples with high histological grade (P ¼ 0.02). These data clearly demonstrate that high levels of A20 expression in breast tumor samples were associated in vivo with poor prognostic tumor markers (ERÀ status, PRÀ status and high histological tumor grade). Therefore, we propose that A20 expression might be a good marker of tumor aggressiveness in breast cancer.
Discussion
The emergence of innate or acquired drug-resistant tumor cells remains a major problem in the treatment of cancers. In breast cancer, adjuvant hormonal therapy of ER þ tumors using the SERM Tam reduces contralateral breast cancer by 50% (EBCTC Group, 1998) . Despite its widespread use in clinical practice, acquired resistance develops in almost all Tam-treated women after long-term medication (Johnston, 1997) . Probably, multifactorial molecular mechanisms leading to Tam resistance remain poorly understood. However, causal association between specific variations of gene expression and modifications in Tam sensitivity has been demonstrated. Indeed, overexpression of HER2/neu (Kurokawa et al., 2000) , ACTR/AIB1 (Louie et al., 2004) , EphA2 (Lu et al., 2003) , Cyr61 (Tsai et al., 2002) , PKC-a (Tonetti et al., 2000) , PKC-d (Nabha et al., 2005) or constitutive active AKT (Campbell et al., 2001; Faridi et al., 2003) has been shown to promote antiestrogen resistance in breast cancer cells. In contrast, overexpression of ER-b1 (Murphy et al., 2005) or downregulation of Bcl2 by an antisense approach (Kim et al., 2005) leads to increased sensitivity to Tam. The identification of these gene expression alterations that could promote modifications in Tam response is of much importance, first to understand the mechanisms involved in Tam resistance, and second to identify reliable markers which could predict endocrine therapy responsiveness. As ERa is a predictive marker of response to endocrine therapy, identification of genes that cocluster with ER status is a first step toward identifying those markers. In this report, we found an intimate relationship between A20 and ER, and demonstrated for the first time that A20 is a new estrogeno-regulated gene. First, the levels of A20 expression were found to be inversely related to ER expression in breast cancer cell lines and in breast cancer tumor samples. Furthermore, E 2 treatment of MCF-7 cells negatively regulated A20 expression. The fact that the pure antagonist ICI 182,780 displayed a reversed pharmacology reinforces the idea that this gene is regulated by E 2 through direct or indirect ER-dependent mechanisms or pathways. Finally, E 2 regulation of A20 gene expression occurs at the transcriptional level, as demonstrated by the gene reporter experiments. The Genomatix GEMS Launcher software (Mu¨nchen, Germany) did not identify any ERE in the 1 kb promoter region of A20 but found NFkB-and Sp1-binding sites. It is well known that NF-kB complexes are able to regulate positively A20 expression and, possibly, in synergy with the Sp1 protein activity (Krikos et al., 1992; Sarma et al., 1995; Ainbinder et al., 2002) . It is also well established that the ER-E 2 complexes can regulate transcription of genes by interacting directly with the Sp1 (Safe, 2001) or the NF-kB (Harnish et al., 2000) transcription factors. In particular, E 2 -ER-NF-kB interaction can lead to the repression of NF-kB's transcriptional activity (Stein and Yang, 1995; Harnish et al., 2000) . Therefore, one could suggest that modulation of NF-kB and/or Sp1 transcriptional activity by ER-E 2 complexes could be one of the mechanisms involved in A20 gene expression regulation by E 2 .
As our data demonstrated a close interplay between A20 and ER expression, we hypothesized that A20 expression could modify endocrine therapy responsiveness. Indeed, we provide evidence that the A20 protein plays a crucial role in the acquired resistance of breast tumor cells to OH-Tam treatment. Clearly, the MCF-7 cells overexpressing the A20 protein developed resistance to the cytotoxic effects of OH-Tam. This effect was not due to the loss or diminution of ER expression (confirmed by Western blotting) or to the loss of functionality of ER because MCF-7-A20 cells were still E 2 -responsive, and this response could be blocked by Tam. Interestingly, the MCF-7-A20 cells were also resistant to ICI 182,780 and to taxol, but not to gemcitabine. These data suggest that A20 may play a key role in the development of resistance to endocrine therapy, and also, that the A20-mediated protection of cells from a specific cytotoxic stimulus depends on the drug considered, and probably on the intracellular pathways specifically targeted by the drug.
Although A20 is an antiapoptotic protein in most cells Jaattela et al., 1996; Ferran et al., 1998) , A20 has also been shown to exert a proapototic action in specific cellular contexts or in response to specific stimuli (Janicke et al., 1994; Patel et al., 2006) . Thus, it was important to investigate the impact of A20 expression on the OH-Tam proapoptotic action in MCF-7 cells. Our data demonstrated that the A20-overexpressing MCF-7 cells were resistant to OH-Tam-induced apoptosis. We clearly demonstrated a different pattern of expression of bcl2, bax, bak and phospho-bad proteins between the MCF-7-A20 and MCF-7-pCIneo cells treated by OH-Tam, demonstrating that A20 expression blocks OH-Tam-induced apoptosis at least in part through the dysregulation of expression of these proteins. Our findings are reinforced by recent data showing that A20 protects murine macrophages from oxidized low-density lipoproteininduced apoptosis through mechanisms involving dysregulated expression of bax, bak, bcl2 and bclxl proteins (Li et al., 2006) . However, future work will be necessary to decipher the exact molecular mechanism mediating the A20's protective effect of MCF-7 cells from OHTam-induced apoptosis.
In addition to the loss of OH-Tam-induced programmed cell death, cell proliferation experiments showed that A20-overexpressing MCF-7 cells also lost their sensitivity to the OH-Tam cytostatic activity and displayed a modified response to the growth stimulatory action of E 2 . Hypersensitivity to E 2 in the MCF-7-A20 cells was shown to be correlated with increased upregulation of four key regulators of the cell cycle: cyclin D1, cyclin D2, cyclin E2 and cyclin A2. These findings are in accordance with recent data showing that A20 is capable of promoting hepatocyte proliferation via decreased expression of the cyclin-dependent kinase inhibitor p21
waf1 (Longo et al., 2005) . Inversely, A20 is also capable of inhibiting smooth muscle cell proliferation through blockade of Rb hyperphosphorylation and increased expression of cyclin-dependent kinase inhibitors p21 waf1 , p27 kip1 and p53 (Patel et al., 2006) , and of blocking murine macrophage proliferation through dysregulation of expression of cyclin B1, cyclin D1, cyclin E, p21 and p73 (Li et al., 2006) . Taken together, these observations strongly suggest that A20's function is not limited to an altered apoptotic response, and that A20 is also capable to regulate directly or indirectly the cell cycle through modulation of the expression of key regulators. These observations are of much importance, in particular in the context of pharmacological resistance of tumor cells.
Taken together, our data have demonstrated that modification of both the proliferating and the apoptotic responses of A20-overexpressing MCF-7 cells is related to alteration of expression of key proteins. However, the mechanism(s) through which A20 leads to such dysregulations remains to be determined. One can suggest that the de-ubiquitination activity of A20 may target cyclin D1, cyclin D2, cyclin E2 and cyclin A2, possibly leading to a decrease in their degradation by the proteasome (Wertz et al., 2004) , and/or that A20's negative-feedback loop which blocks NF-kB activation and cellular survival led to OH-Tam resistance (Storz et al., 2005) .
Previous studies have shown a causal association between specific variations of gene expression and modifications both in Tam and E 2 response (Tsai et al., 2002; Yue et al., 2002; Faridi et al., 2003; Lu et al., 2003; Martin et al., 2003; Berstein et al., 2004; Louie et al., 2004) . Interestingly, the resultant phenotype of the MCF-7-A20 cells (OH-Tam resistance and hypersensitivity to E 2 ) is very close to that displayed by previously characterized OH-Tam cellular clones (Vendrell et al., 2005) . Inversely, we also observed that two independent Tam-resistant cell lines models possessed greater amounts of A20 than their Tam-sensitive counterpart. Overall, our data clearly demonstrates a causal association between A20 expression and modified ER-dependent response.
ER status is an important parameter in breast cancer management, and ER þ breast cancers have a better prognosis than ERÀ tumors, which are more aggressive and invasive than ER þ tumors (Thompson et al., 1992; Pichon et al., 1996) . Because elevated expression of genes involved in the mechanisms of chemoresistance have frequently been associated with tumor aggressiveness, we explored A20 expression in a collection of ER þ and ERÀ breast tumors. We demonstrated that A20 expression negatively correlates with ERa expression and is significantly increased in tumors with poor prognostic markers, that is, ERÀ status, PRÀ status and high histological grade. Our data strongly suggest that increased expression of A20 in breast carcinoma is associated with an aggressive phenotype. Interestingly, A20 expression has been closely associated with resistance to O6-alkylating agents in glioblastoma cells and has been proposed as a predictive marker associated with patient survival (Bredel et al., 2006) . These observations lead us to propose A20 as a potential prognostic marker of breast cancer.
In conclusion, our study demonstrates that A20 gene expression regulation involves ERa-dependent pathways. We have also shown that A20 overexpression confers OH-Tam resistance to MCF-7 cells and is implicated in the mechanisms of increased sensitivity to E 2 growth-stimulating action and blocking of OHTam cytostatic and apoptotic activities. These actions may be related to the dysregulation of expression of key proteins like cyclins and proteins belonging to the bcl2 family. Finally, A20 gene expression coclusters with the ER status and poor prognostic markers in breast tumor samples. In summary, A20 represents a potential prognostic marker of breast cancer and a promising target for improving the endocrine treatment approach and for developing new strategies to prevent the emergence of acquired mechanisms of drug resistance in breast cancer.
Materials and methods
Cell culture
The ER þ (MCF-7, ZR-75-1, T-47D, BT-474) and ERÀ (MDA-MB-175, MDA-MB-231, MDA-MB-435, MDA-MB-453) breast cancer cell lines were grown according to the ATCC's recommendations. MVLN, a human breast carcinoma cell line derived from MCF-7, and two MVLN-derived OH-Tam-resistant cell lines (called CL6.8 and CL6.32) were grown as previously described (Demirpence et al., 1993) . The breast carcinoma VP229 and Tam-resistant VP267 cells were grown as previously described (McCallum and Lowther, 1996) . Cells were purged for 4 days in Dulbecco's modified Eagle medium (DMEM) without phenol red and supplemented with 3% steroid-depleted, dextran-coated charcoal-treated fetal calf serum (DCC medium), then treated with vehicle, 10 À9 M E 2 , 2 Â 10 À7 M OH-Tam or 10 À7 M ICI 182,780.
Breast tumor samples
Sixty-nine primary tumors from patients with no therapy before surgery were collected from postmenopausal women at the Pathology Department of Val d'Aurelle Cancer Center (Montpellier, France). The malignancy of infiltrating carcinomas was scored according to the histopronostic system of Scarff-Bloom-Richardson (Bloom and Richardson, 1957) . The ER þ status was determined at the protein level by a radio-ligand binding assay (with a cutoff level for positivity set at 10 fmol/mg of protein according to the WHO typing system) and confirmed by a ERa RTQ-PCR assay. The PR status was measured at the protein level by a binding assay as previously described (De Goeij et al., 1988) .
A20 gene expression RTQ-PCR analysis
Total RNA from cell lines or breast tumor samples was extracted by cesium chloride ultracentrifugation, and RNA integrity was checked using the BioAnalyser 2100t (Agilent Technologies, Palo Alto, CA, USA). One microgram of total RNA from each sample was reverse-transcribed, and RTQ-PCR measurements were performed as described previously (Vendrell et al., 2004) using the forward primer 5 0 -CCTTGC TTTGAGTCAGGCTGT-3 0 and the reverse primer 5 0 -TAAG GAGAAGCACGAAACATCGA-3 0 . All measurements were normalized to the expression of the 28S ribosomal gene.
For the A20 gene expression measurements in the 69 breast tumor samples, the amount of target, normalized to the expression of the 28S gene and relative to calibrators composed of four normal breast tissue samples, was calculated as follows:
, where E is the efficiency of the RTQ-PCR reaction calculated with the slope of the corresponding standard curve, C T the threshold cycle, and DC T ¼ (C T target geneÀC T 28S).
Statistical analyses were performed using the MannWhitney test and the Spearman's rank correlation test. Differences between groups were judged significant at a confidence level greater than 95% (Po0.05).
Luciferase assay
The A20 Firefly luciferase reporter plasmid (A20-Luc) containing the proximal promoter of A20 was kindly provided by Dr Dikstein (Yamit-Hezi et al., 2000) . MCF-7 cells were purged in DCC medium for 4 days and then plated at 360 000 cells/well on a six-well tissue-culture plate. After 24 h, cells were transfected using lipofectamine Plus (Invitrogen, Cergy Pontoise, France) with 700 ml of DNA precipitate containing 1.5 mg A20-Luc and 200 ng pTK-RL, the Renilla luciferase plasmid serving as transfection efficiency control. Six hours after transfection, cells were washed twice with PBS and then cultured for 48 h in DCC medium supplemented or not with 10
À9 M E 2 . Luciferase activity was assessed using the Dual-luciferase reporter assay (Promega, Charbonnieres, France) according to the manufacturer's recommendations. A control experiment of E 2 response was performed using 1.5 mg ERE (Estrogen Response Element) luciferase reporter plasmid (ERE-Luc).
MCF-7-A20 stable transfectants
The cDNA encoding the A20 gene was obtained by PCR amplification from the pJDM-A20 plasmid generously provided by Dr Vincenz (Zetoune et al., 2001 ) using the forward primer 5 0 -TACCGGAATTCCGGATGGCTGAACAA-3 0 and the reverse primer 5 0 -CGGTGCTCTAGAGCATTAGCCAT ACATC-3 0 . To construct the A20 expression plasmid (pCIneo-A20), the cDNA was cloned in the pCIneo plasmid at the EcoRI and XbaI sites and sequenced. MCF-7 cells were then stably transfected with 6 mg of either empty pCIneo or pCIneo-A20. Transfected cell populations were selected in the presence of 1 mg/ml of G418 (Invitrogen, Cergy Pontoise, France). We then isolated two MCF-7-pCIneo cellular clones (called 1E8 and 3B3) and two MCF-7-A20 cellular clones (called 1F8 and 2C6) . Viable cells after 4 days of treatment with OH-Tam (10 À7 M) were detected by using the neutral red cytotoxicity assay as previously described (Vendrell et al., 2005) IC 50 values and relative resistance ratio of A20-overexpressing MCF-7 cells -MTT test The cells were plated at 3000 cells/well on a 96-well tissue culture plate in DMEM medium and treated for 5 days with different concentrations of OH-Tam (10 À8 to 10 À4 M), gemcitabine (10 À10 M to 3 Â 10 À7 M), taxol (10 À10 to 3 Â 10
or ICI 182,780 (10 À10 -10 À6 M) The medium was then removed and the cells were incubated for 2 h at 371C with methylthiazoletetrazolium (MTT) (500 mg). The supernatant was removed, 300 ml of isopropanolHClH 2 O (90:9:1, by vol) was added to solubilize the formazan crystals, and the absorbance was measured at 540 nM. The IC 50 was defined as the concentration giving rise to a 50% reduction in cellular viability.
Cell proliferation analysis
The cells were purged in DCC medium for 4 days and plated at 10 000 cells/well on a 96-well tissue-culture plate in DCC medium. One day later, the cells were treated for 4 days with vehicle, 10 À9 E 2 , 10 À7 M OH-Tam or E 2 þ OH-Tam. Proliferating cells were analysed using the Cell Proliferation ELISA, 5-bromo-2 0 -deoxyuridine (BrdU) kit (Roche, Meylan, France). Briefly, the cells were labeled for 24 h with BrdU and the labeled nuclei were identified using a specific anti-BrdU antibody according to the manufacturer's recommendation.
Detection of apoptosis by Annexin-V staining
The cells were grown for 4 days in the absence of any treatment or in the presence of 5 Â 10 À6 M OH-Tam. Apoptotic cells were detected using the Annexin-V-FLUOS Staining Kit (Roche). Briefly, cells were harvested, washed twice, labeled with fluorescein isothiocyanate (FITC)-Annexin-V and analysed by flow cytometry as previously described (Vendrell et al., 2005) .
Western blot
Cell extract preparations and Western blot analysis were performed as described previously (Vendrell et al., 2004) . The A20, bak, bax, cyclin D2 and cyclin E2 antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), cyclin A2 and a-tubulin antibodies from Sigma Chemical Co. (St Louis, MO, USA), bcl2 antibody from Dako (Glostrop, Denmark), cyclin D1 antibody from Cell Signaling (Beverly, MA, USA) and phospho-Bad antibody from Serotec (Kinglington, UK).
